Curis Lifesciences Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹1 Cr
QJun 2024
In Jun 2024, Curis Lifesciences (CURIS) reported revenue ₹9 Cr and net profit ₹1 Cr. For annual financials, live price and key ratios, visit CURIS stock overview.
Curis Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CURIS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Jun 2024 | QoQ | YoY |
|---|---|---|---|
| Revenue (₹ Cr) | 9 | - | - |
| Net Profit (₹ Cr) | 1 | - | - |
| EBITDA (₹ Cr) | 3 | - | - |
| EPS (₹) | 24.00 | - | - |
| Operating Margin (%) | 30.0% | - | - |
CURIS Share Price Trend — 1-Year Movement Across Quarterly Results
Curis Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices.
CURIS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Curis Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1808.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 139.1 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6502.5 | 2,860 | 689 | +7.1% | - | 24.1% | 250.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹142,059.09 Cr | 4185.1 | 3,219 | 591 | +11.3% | - | 18.4% | 238.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹110,348.15 Cr | 1322.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 81.8 |
|
Cipla
Sept 2025 |
₹105,996.98 Cr | 1309.6 | 7,716 | 1,353 | +12.0% | - | 17.5% | 78.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores